cost

exhibit

DarioHealth Corp

manipulation

but manipulation and a little bit of profit taking on the daily.

I mean, this is a poster child for manipulation.

Manipulation - this stock price isnt real.

$DRIO Serious manipulation going on this morning.

quot

$DRIO A 3rd consecutive &quot;horrendous&quot; quarter put up by smoke and mirrors accounting.

And when you ask these &quot;bulls&quot; for DD - you know, to give them the benefit of the doubt - they scream personal insults.

but it&#39;s honestly kind of annoying when I keep seeing &quot;news any day&quot; for so many days in a row.

but the fact that I can&#39;t Google the company and this write up and have it generate a correct link, in addition to a lack of any &quot;about&quot; information in the write-up raises a big question mark for me.

joke

$DRIO C’mon Bulls…this is total bullshit here.

$DRIO still a complete joke for SP and market movement,

$DRIO Why does it always shows ridiculous price AH? Lol

profit

And paying a premium cutting into profits.

volume

Jan 26th it closed at $5.97
This is down $1.49 over 20 % in a month
But it’s low volume guys.

In this macro environment where everyone is looking to cut costs, these studies will help drio win health plan contracts over the competition.

$DRIO I’ve never seen anything like this…Best-in-Class revenue growth by miles for 1/10th of the valuation cost; major strategic partners $CVS &amp; $SNY; plenty of cash.

Employers are not cutting on healthcare costs. Recession-proof.

We now see double-digit non-GAAP EPS growth each period [quarterly, annual] into FY23, as seen in Exhibit 2.

growth

$DRIO even in this crap market this should be 10$ half the multiple of similar comps with twice the growth!

The growth of the B2B business has resulted in an overall significant improvement in the financial profile of the Company.

They have reached operating leverage and continued growth will make this company soon profitable.

I&#39;m excited for Matt to join at this juncture in our growth, as we recently signed our 100th contract and the market demand for integrated solutions continues to grow.

Looking at the last year, $DRIO shows a very strong growth in Revenue.

Looking forward to another year of outstanding revenue growth, margin inflection, &amp; new major partners.

Premier growth profile, inflecting margins &amp; profitability, small float, dirt cheap valuation.

revenue

Its a big freaking revenue funnel to start!! !

- 100 contracts reached 
- obviously bullish JPM conference 
- pre-announced revenue beat and likely EPS beat
- DXCM partnership 

This all happened in 5 weeks.

We believe that the expected 2022 results are especially exciting because B2B revenue represents the majority of our revenue for the first time.

$DRIO $AMWL $TDOC - drio continues to execute in the digital health space - growing revenues and reducing burns - signing bigger and bigger names : no brainer if u love the space

First-time revenue guide for 2023 could also catapult this to new highs.

Look at my sweetheart stock FLNT -- on pace for 400M in annual revenue and PROFITABLE!

bull

Volume yesterday suggests bulls are in it to win it.

$DRIO  
 
Bulls - notice an increase in the number of people last 12 hours telling you this stock is a good one

Boston Properties, Inc.

So if I’m assigned the cost basis will be ~$35 not too bad for long term hold

Owned by BXP (NYSE: BXP), the world-class observatory, designed with the adventurer in mind, features state-of-the-art immersive experiential exhibits, 360° breathtaking views of the city, and more.

company

Buy slowly and patiently in good companies. Cheers!

BXP Maintains Industry Leadership, Improves Ranking in Newsweek’s List of the Most Responsible Companies For 2023 https://conferencecalltranscripts.com/summary/?id=483590&amp;pr=true $BXP

BXP Maintains Industry Leadership, Improves Ranking in Newsweek’s List of the Most Responsible Companies For 2023 https://conferencecalltranscripts.com/summary/?id=483589&amp;pr=true $BXP

$BXP https://www.stockilluminati.com/bxp/news.php - BXP Maintains Industry Leadership, Improves Ranking in Newsweek’s List of the Most Responsible Companies For 2023

$BXP BXP Maintains Industry Leadership, Improves Ranking in Newsweek’s List of the Most Responsible Companies For 2023
https://www.stocktitan.net/news/BXP/bxp-maintains-industry-leadership-improves-ranking-in-newsweek-s-ae2ju206lug6.html

BXP ranked first in the Real Estate &amp; Housing industry with an increased ranking of 29th overall out of the 500 companies included and had the third highest environmental score.

industry

price

$BXP  
 
 Signal Update  
 
 As of today, BXP is up +3.77 percent from buy price 72.29 in 8days and on track to achieve target price 75.71.

$BXP  
 
 Signal Update  
 
 As of today, BXP is up +2.55 percent from buy price 72.29 in 8days and on track to achieve target price 75.71.

Madrigal Pharmaceuticals Inc

data

$CACO Perhaps the biggest kick in the nuts is seeing this garbage $MDGL hit all time highs yesterday at $315 after reporting NASH data.

$MDGL as good as the phase 3 data was this is fuckin nuts and the manipulation couldn&#39;t be more blatant.

Data is not even as good as some competitors

$MDGL So many irregularities with the data.

$MDGL if you look at the data closer, it is actually a disgused failure.

This market is a shit show that wants to collapse and any bad data this will get eviscerated!

The data is dropping with an 830am eastern time conference call.

Leaving data to last possible minute isn’t a good sign.

market

$MDGL this stock market is so full of shit.

$MDGL $VKTX markets going up and this aint.

Suddenly you realize the market is not as big as they are claiming!

$MDGL This is a perfect example of what is wrong with this market still.

show

$MDGL Today is going to be an absolute shit show likely with markets tanking and no news here.

strike

suck

$MDGL For all the mean and rude assholes out there.

WTF Jerry even the neighborhood asshole can be civil.

$MDGL down down down let’s go bears fuck this piece of crap

$MDGL a lot of options for tomorrow are being fucked with.

$MDGL Benefits of an ORAL formulation (versus injections) 

Patients: ~75% of patients would be very to extremely likely to try resmetirom if approved and cost was not an issue

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

I don’t have to wait for fda approval for such low MC like ETNB is good promising data in next 3 weeks .. it can 3x my investments .. like AKRO is seating at 2B… ETNB HAS a strong potential for 2-3x from here next 3-4 weeks

This is an outstanding setup for $VKTX&#39;s VK2809 P2b study which is scheduled to release data in Q2 2023.

Well for genius shorts who can&#39;t read medical data, this is a GREAT shorting opportunity.

$VKTX from what I&#39;ve read from the preliminary trial data, the molecule is good, maybe better than $MDGL and has applications in weightloss.

$MDGL $ALT $TERN will wind up better with much better data.

With slam-dunk efficacy data and two years worth of safety data with no significant adverse safety events reported, Resmetirom has a clear path forward to accelerated approval.

$MDGL their PhIII data are so resoundingly positive that this has been termed a “watershed moment” and a “shock win” for the company.

$MDGL cheers bulls great finish to the year!

$MDGL congrats to all longs and bulls here.

$MDGL benefits of owning low float market king bull.

$MDGL  
The MM now  
ok guys we did a great job this week let&#39;s celebrate Christmas and enjoy the fool&#39;s bulls&#39; money

$MDGL The horns on this bull are massive.

$MDGL - Congrats bulls on MDGL&#39;s stellar P3 performance and strong price run especially leading up to the holidays.

trial

$MDGL this is the cream of the crop, we already have stellar phase 3 results in the books.

$MDGL nice opportunity to add a few hundred shares here 😆  the celebration of shorts today reminded me when the stock price dropped sharply by 27% in a couple of days before trial readout.

Based on my multi year knowledge in NASH field, mdgl management so far did the best execution of clinical development - too many things to exemplify here!

Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.

After reaching its endpoints on its Phase 3 data we have seen a $240 spike!

Plus, remember this company is light years ahead of its competitors none of whom have had success with Phase 3. Bullish!

$VKTX Truth: VKTX increased more than 100% last 3 days since $MDGL has Phase 3 results.

Top Stocks matching your search for "cost exhibit"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

DRIO

DarioHealth Corp

-25.48%

$5.77 - $4.30

Dec, 19, 2022

Dec, 12, 2022

BXP

Boston Properties, Inc.

-31.61%

$73.04 - $49.95

Mar, 19, 2023

MDGL

Madrigal Pharmaceuticals Inc

-10.68%

$275.00 - $245.64

Mar, 16, 2023

DRIO

DarioHealth Corp

-25.48%

$5.77 - $4.30

Dec, 19, 2022

Dec, 12, 2022

Oct, 13, 2022

BXP

Boston Properties, Inc.

-31.61%

$73.04 - $49.95

MDGL

Madrigal Pharmaceuticals Inc

-10.68%

$275.00 - $245.64

Mar, 16, 2023